DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2209178/ligand-pharmaceuticals-lgnd-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2209178 Jan 11, 2024 - Ligand Pharmaceuticals (LGND) closed at $72.19 in the latest trading session, marking a -1.84% move from the prior day. 0

https://www.zacks.com/stock/news/2241058/ligand-pharmaceuticals-lgnd-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2241058 Mar 14, 2024 - Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close. 0

https://www.zacks.com/stock/news/2251479/ligand-pharmaceuticals-lgnd-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2251479 Apr 05, 2024 - Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day. 0

https://www.zacks.com/stock/news/2259547/will-alkermes-alks-proprietary-drugs-aid-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2259547 Apr 22, 2024 - Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024. 0

https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438 Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia. 0

https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461 Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome. 0

https://www.zacks.com/stock/news/2207168/ligand-lgnd-up-9-on-fda-nod-for-molluscum-infection-gel?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207168 Jan 08, 2024 - Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum. 0

https://www.zacks.com/stock/news/2221375/ligand-pharmaceuticals-lgnd-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2221375 Feb 05, 2024 - In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $74.72, denoting a +0.24% change from the preceding trading day. 0

https://www.zacks.com/stock/news/2242754/ligand-lgnd-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2242754 Mar 19, 2024 - According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.zacks.com/stock/news/2250019/ema-accepts-rocket-rckt-gene-therapy-filing-for-fanconi-anemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250019 Apr 03, 2024 - The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow. 0